Information Provided By:
Fly News Breaks for March 2, 2020
Mar 2, 2020 | 11:15 EDT
SVB Leerink analyst Jonathan Chang raised the firm's price target on Karyopharm to $30 from $22 after the company reported positive top-line results from the Phase 3 BOSTON study of Xpovio in patients with relapsed/refractory multiple myeloma. The analyst, who said a positive BOSTON study outcome was in-line with his expectations, keeps an Outperform rating on the shares.